Kornimate/medical-research-clean huggingface dataset:
proleukin in combination with rituxan in patients with low-grade non-hodgkin's lymphoma who have previously failed rituxan treatments

Conditions: Lymphoma, Non-Hodgkin

Summary: the purpose of this study is to determine the safety and effectiveness of combination therapy with proleukin and rituxan on patients with low-grade non-hodgkin's lymphoma who have previously failed rituxan treatments.


Eligibility criteria:
diagnosis and disease status: * subjects with cd20+, b-cell, non-hodgkin's lymphoma of low-grade or follicular histology with measurable relapsed or unresponsive disease after prior therapy; mantle cell and chronic lymphocytic leukemia subtypes are excluded. * subjects who previously received a single-agent course of rituximab and showed no tumor response, or had a response lasting \< 6 months. the previously administered rituximab must have included at least 75% of the standard 4-week regimen (4 x 375 mg/m2). a record of the previous rituximab treatment and response must be available as a source document at the site. exclusion: * subjects who showed no tumor response or a response lasting \<6 months to treatment with rituximab in combination with chemotherapy or another therapeutic modality (radiation or radioimmunoconjugates). * hiv positive. * symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism. * clinically significant cardiac, pulmonary, and /or hepatic dysfunction (if subject has history of congestive heart failure or myocardial infarction, must have been stable for at least 6 months, and have no current symptoms * if cardiac ejection fraction has been measured, it must be greater than 50%.

Keywords: low-grade or follicular non-hodgkin's lymphoma